Caution Advised In China’s Digital Dash Into Healthcare’s Future
This article was originally published in PharmAsia News
China’s digital healthcare market is set to expand massively and reach $110bn by 2020, disrupting the industry, creating fresh opportunities and casting aside those who don’t keep up with the times. However, experts caution that digital solutions are no panacea unless they have real patient-centered value.
You may also be interested in...
Digital physician engagement channels appear to be closing in on the traditional face-to-face approach, with China surging ahead on the digital path. The US and China appear more or less in sync when it comes to self-directed web-detailing, while AstraZeneca, Lilly and GSK lead the charts in terms of digital engagement as perceived by healthcare professionals, a new survey shows.
Solid fundamentals in the Asia-Pacific healthcare market are continuing to attract significant investment and M&A activity with no signs of a slowdown, despite fears over China’s economic growth and negative factors in the wider global economy. Medtech, digital health and health services are all set to benefit, experts say.
Suzhou-based Innovent Bio becomes the fourth biotech from mainland China to go public in Hong Kong, and its strong first-day performance may have given the seemingly spooked market so far for such companies a shot of confidence.